Skip to Main Content

Rise and shine, folks, another busy day is on the way. We can tell because, once again, the short person is already hunched over a laptop for a new round of learning and the official mascot is bounding about the Pharmalot campus in search of varmints. As for us, we are busy doing the usual — brewing cups of stimulation and foraging for items of interest. What else would be doing? So here is the latest. We hope your journey goes well today and you conquer the world. Meanwhile, stay safe and stay in touch. …

This is the eve of a major speech by President Biden, but it’s anyone’s guess what he will say about drug pricing, STAT explains. Swirling rumors have roiled the pharmaceutical industry and Congress over the past week. Top leaders in Congress have no idea what the White House actually supports. Sound familiar? Democratic leaders in the White House and Congress clearly aren’t on the same page, a division reminiscent of the years-long infighting over policy under Republican leadership in Washington — an infighting Democrats often criticized.


U.S. Trade Representative Katherine Tai on Monday met virtually with top executives of Pfizer (PFE) and AstraZeneca (AZN) to discuss a proposed waiver of certain intellectual property rights in response to the Covid-19 pandemic, Reuters reports. Members of the World Trade Organization are due to discuss a proposal by India and South Africa to waive certain provisions of the WTO’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) on April 30, but the U.S. and a few other big countries have blocked such a move.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!